BRCA1 and adenocarcinoma: NCCN guidelines included this criterion in a 2019 update [12] based on the research that 2–5% of unselected adenocarcinoma patients harbor BRCA1/2 pathogenic variant [28], making BRCA1/2 pathogenic variants the most common genetic cause of pancreatic cancer [29] and so, an attractive candidate gene for genetic testing.